Eli Lilly Reports Strong Q1 2026 Earnings and Announces New Obesity Drug Approval

Eli Lilly (LLY) reported strong Q1 2026 earnings with robust revenue growth and announced the FDA approval of its new obesity drug Koundeo. The drug, a GLP-1 agonist in pill form, is expected to drive future growth and has already shown strong consumer and healthcare professional awareness.

By Motley Fool Transcribing, The Motley Fool Thu, April 30, 2026 at 6:51 PM GMT+3 34 min read · Yahoo Finance · April 30, 2026, 15:51 UTC

Tickers: $LLY

Topics: Drug Launch Earnings Call FDA Approval Pipeline Development Revenue Growth

Read the full article at Yahoo Finance

More World news

Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC